CUV

0.85%

$15.37 clinuvel pharmaceuticals limited

Disc makes zero revenue and burns through cash, whilst CUV...

First 94 Last

Share
Profile

Follow
TheAnalyst007

15,488 Posts.

3949

03/05/24

11:35

Post #: 73647981
Share

Originally posted by Silverchair: ↑

The best comparison stock to Clinuvel is Disc Medicine which just runs a few Phase 1 and 2s with their lead drug candidate targeting the modest EPP market. The Disc drug hoping to one day compete with CUV recently flunked their trial and the Disc share price took a big hit, but they are still amazingly valued much higher than CUV. I don't think Disc gets the constant attention from shorters that Clinuvel has had for 5 years but they are undoubtedly better than CUV at attracting investor interest despite being a MUCH riskier investment proposition and a much less advanced company. Hopefully the new Clinuvel US appointee can help address this imbalance because CUV are very poor in this regard and a possible simple upgrade from their current listing in the States would be a very positive move.

For comparison purposes, Disc LOST $76.4 Million USD ($116 M AUD) last year running Phase 1 and 2s, while CUV made last FY $31.6 Million PROFIT after taxes. Clinuvel already running a phase 3 into a blockbuster indication in Vitiligo which we know works and this with an already FDA, EMA approved drug that is proven safe, so the process for approval is much easier than a New Drug application which Disc will have to file if they ever get to that point. In my opinion Clinuvel will have Vitiligo approved and commercialised well before Disc can even attempt to enter the EPP market - and Disc have many big hurdles to get over before they get there. Loss making Disc makes significant losses, which is ok for this stage, but they may never even get any drug approved and they certainly don't make great profits like money-printing CUV yet they are valued at ~ $1.1 Billion AUD while CUV languishes at about $0.7 Billion (with $180M cash). Risk/reward is curious with Disc valued entirely on hope and CUV with no future cash flow valuation for Vitiligo or anything else.

The average analyst PT for Clinuvel is mid $20s just for EPP and only one analyst is pricing in Vitiligo right now and they have a PT around $50. If CUV had the same valuation as loss making and very risky Disc they would have a SP of ~$22 which is still under the average analyst PT for CUV just on EPP. With only 50 Million CUV shares on issue, and a share buyback just started that will remove 1.5 Million CUV from circulation, you would think US investor relations could make a pretty good investment thesis for CUV but they might need that pink sheet upgrade to help their case.

All IMO DYOR

Expand

Disc makes zero revenue and burns through cash, whilst CUV prints cash and has a far bigger pipeline. Yet somehow this is valued less...

Sooner or late CUV's price will have to rerate imo. Sure things move slow, but it's significantly better than most companies.

CUV Price at posting: $15.02 Sentiment: Buy Disclosure: Held
6 Upvote

1 Great analysis

Reply

Top Stories

LRV

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

AVA

Ava Risk Group expands US presence with A$0.7M Substation Deal

SVL

Silver Mines models five new calderas close to 396Moz Bowdens deposit

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

CMX

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

RCE

Recce's R327 found effective against E.coli during clinical trial

LU7

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

There are more pages in this discussion • 13 more messages in this thread...

First 94 Last

Add CUV (ASX) to my watchlist

(20min delay)
Last $15.37		Change 0.130(0.85%)		Mkt cap ! $770.0M

Open	High	Low	Value	Volume
$15.36	$15.54	$15.18	$1.274M	82.63K

Buyers (Bids)

No.	Vol.	Price($)
1	237	$15.31

Sellers (Offers)

Price($)	Vol.	No.
$15.50	282	2

View Market Depth

No.	Vol.	Price($)
1	5	15.200
1	100	15.170
1	989	15.120
1	2000	15.020
1	2	15.000

Price($)	Vol.	No.
15.780	500	1
15.850	1000	1
15.860	193	1
15.880	500	1
15.900	500	1

Last trade - 16.10pm 28/06/2024 (20 minute delay)

CUV (ASX) Chart

Disc makes zero revenue and burns through cash, whilst CUV...

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Recce's R327 found effective against E.coli during clinical trial

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Disc makes zero revenue and burns through cash, whilst CUV...

Top Stories

Larvotto identifies new exploration target at NSW's Hillgrove, boosting shares by nearly 20%

Microcap Wrap: 5 explorers with news out today

Ava Risk Group expands US presence with A$0.7M Substation Deal

Silver Mines models five new calderas close to 396Moz Bowdens deposit

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ChemX Materials kicks off first stage works at WA high purity alumina pilot

Wealth Within weighs in on shock 4% inflation read – and stocks that could survive the gloom

Recce's R327 found effective against E.coli during clinical trial

Lithium Universe (ASX:LU7) board visits Quebec to engage key stakeholders

Week 26 Wrap: Cerberus of inflation barks – rents, electricity & fuel – and world watches two elders bicker

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News